NanoVibronix, Inc.

As of November 15, 2021, NanoVibronix, Inc. is considered risky and overvalued due to poor financial metrics and a significant decline in stock performance, with a year-to-date return of -89.66% and a five-year decline of -99.49%.

As of November 15, 2021, NanoVibronix, Inc. is considered a risky investment and appears overvalued due to poor financial metrics, including a Price to Book Value of 0.07 and significant operational challenges reflected in its negative EV to EBITDA and EV to EBIT ratios, alongside a year-to-date decline of 86.05% compared to a 2.44% gain in the S&P 500.

As of June 17, 2025, the technical trend is bearish, indicated by negative signals from the MACD, Bollinger Bands, and moving averages, despite some bullishness in the monthly OBV.

As of March 2022, the management team of NanoVibronix, Inc. includes Chairman Christopher Fashek, CEO Brian Murphy, Chief Medical Officer Harold Jacob, Directors Martin Goldstein, Michael Ferguson, and Thomas Mika.

NanoVibronix, Inc. is a medical device company specializing in noninvasive devices for wound healing and pain therapy, classified as a micro-cap with a market cap of $2.33 million. As of March 2025, it reported net sales of $1 million and a net loss of $2 million.

As of Jun 18, NanoVibronix, Inc. has a market capitalization of 2.33 million and reported net sales of 2.66 million with a net profit of -5.62 million over the latest four quarters. Shareholder's funds are at 0.63 million, and total assets amount to 3.63 million.